Terms: = Brain cancer AND RPL22, EAP, 6146 AND Treatment
13 results:
1. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung cancer with Rearranged during Transfection (RET) Gene Rearrangement.
Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
[TBL] [Abstract] [Full Text] [Related]
2. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (eap).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract] [Full Text] [Related]
3. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract] [Full Text] [Related]
4. Radiotherapy-induced glioblastoma: distinct differences in overall survival, tumor location, pMGMT methylation and primary tumor epidemiology in Hong Kong chinese patients.
Woo PYM; Lee JWY; Lam SW; Pu JKS; Chan DTM; Mak CHK; Ho JMK; Wong ST; Po YC; Lee MWY; Chan KY; Poon WS
Br J Neurosurg; 2024 Apr; 38(2):385-392. PubMed ID: 33576706
[TBL] [Abstract] [Full Text] [Related]
5. treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience.
Bernstock JD; Alva E; Cohen JL; Lobbous M; Chagoya G; Elsayed GA; Orr BA; Rozzelle C; Rocque B; Blount J; Johnston JM; Li R; Fiveash JB; Dhall G; Reddy AT; Friedman GK
Pediatr Blood Cancer; 2020 Mar; 67(3):e28119. PubMed ID: 31850678
[TBL] [Abstract] [Full Text] [Related]
6. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Crinò L; Bronte G; Bidoli P; Cravero P; Minenza E; Cortesi E; Garassino MC; Proto C; Cappuzzo F; Grossi F; Tonini G; Sarobba MG; Pinotti G; Numico G; Samaritani R; Ciuffreda L; Frassoldati A; Bregni M; Santo A; Piantedosi F; Illiano A; De Marinis F; Tamberi S; Giannarelli D; Delmonte A
Lung Cancer; 2019 Mar; 129():35-40. PubMed ID: 30797489
[TBL] [Abstract] [Full Text] [Related]
7. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
Bracarda S; Galli L; Maruzzo M; Lo Re G; Buti S; Favaretto A; Di Costanzo F; Sacco C; Merlano M; Mucciarini C; Zafarana E; Romito S; Maestri A; Giorgio CG; Ionta MT; Turci D; De Giorgi U; Procopio G; Cortesi E; Giannarelli D; Porta C
Future Oncol; 2018 Jun; 14(14):1347-1354. PubMed ID: 29774766
[TBL] [Abstract] [Full Text] [Related]
8. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O; Vogelzang NJ; Sweeney C; Fernandez DC; Almeida F; Iagaru A; Brown A; Smith MR; Agrawal M; Dicker AP; Garcia JA; Lutzky J; Wong YN; Petrenciuc O; Gratt J; Shore ND; Morris MJ;
Oncologist; 2018 Feb; 23(2):193-202. PubMed ID: 29183960
[TBL] [Abstract] [Full Text] [Related]
9. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Ahmad SS; Qian W; Ellis S; Mason E; Khattak MA; Gupta A; Shaw H; Quinton A; Kovarikova J; Thillai K; Rao A; Board R; Nobes J; Dalgleish A; Grumett S; Maraveyas A; Danson S; Talbot T; Harries M; Marples M; Plummer R; Kumar S; Nathan P; Middleton MR; Larkin J; Lorigan P; Wheater M; Ottensmeier CH; Corrie PG
Melanoma Res; 2015 Oct; 25(5):432-42. PubMed ID: 26225580
[TBL] [Abstract] [Full Text] [Related]
10. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
Queirolo P; Spagnolo F; Ascierto PA; Simeone E; Marchetti P; Scoppola A; Del Vecchio M; Di Guardo L; Maio M; Di Giacomo AM; Antonuzzo A; Cognetti F; Ferraresi V; Ridolfi L; Guidoboni M; Guida M; Pigozzo J; Chiarion Sileni V
J Neurooncol; 2014 May; 118(1):109-16. PubMed ID: 24532241
[TBL] [Abstract] [Full Text] [Related]
12. Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C
Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748
[TBL] [Abstract] [Full Text] [Related]
13. An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.
Ohtsu A; Yoshida S; Saito D; Shimada Y; Miyamoto K; Fujii T; Yoshino M; Yoshimori M
Jpn J Clin Oncol; 1991 Apr; 21(2):120-4. PubMed ID: 2067126
[TBL] [Abstract] [Full Text] [Related]
